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OBJECTIVE To determine amongst patients with axSpA 1) factors associated with decreased spinal 
mobility and 2) whether poor mobility is a predictor of response to anti-TNFα therapy.
METHODS A prospective UK cohort study of persons meeting ASAS criteria for axial spondyloarthritis. At 
recruitment, clinical and patient-reported factors independently associated with spinal mobility 
(measured by BASMI) were determined. Amongst those commencing anti-TNFα therapy, factors which 
were independent predictors of response was determined using ASAS, quality of life and ASDAS response 
criteria. 
RESULTS 1,960 participants were eligible; 70% male, median age 48 years (inter-quartile range 37,59), 
median BASMI score 3.6(2.2,5.3). Factors independently associated with poor spinal mobility were: 
poorer function; meeting x-ray criteria for AS; longer symptom duration; higher levels of inflammation 
(measured by CRP); older age; male gender; not being currently employed and lower levels of education. 









This article is protected by copyright. All rights reserved
was an independent predictor of not meeting response criteria for ASAS20 (OR per increasing score 
0.80(0.66, 0.98)), ASAS40 (0.69(0.50, 0.95)), quality of life (measured by ASQoL) (β 0.64(0.26, 1.02)), but 
was not related to meeting ASDAS response criteria.
CONCLUSIONS: BASMI was estimated moderately well by other routinely measured factors in patients 
with axSpA and was an independent predictor of response to biologic therapy for some, but not all, 
commonly used measures. Consensus around its role in disease monitoring and clinical decisions, 
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Significance & Innovations
 BASMI could be reasonably well estimated in half of patients.
 BASMI was estimated using a combination of socio-demographic, clinical and biological markers. 
 BASMI is an independent predictor of treatment response for measures based on BASDAI and/or 
quality of life, but not ASDAS.
 It will be important to determine how BASMI should be incorporated into disease monitoring and 
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Introduction
Axial spondyloarthritis (axSpA) is an inflammatory rheumatic disease of the axial skeleton, which is 
characterised predominantly by low back pain, stiffness, and sacroiliitis (1,2). The disease affects between 
0.1% and 1.4% of the population, depending on area of the world (3,4). 
The impairment of spinal mobility is considered one of the central outcomes in axSpA and has been 
included in the core set of domains for the evaluation of patients in clinical practice, as defined by the 
Assessment of Spondylarthritis international Society (ASAS) (5–7). The Bath Ankylosing Spondylitis 
Metrology Index (BASMI), an index of spinal mobility; consisting of four spinal (cervical rotation, tragus-to-
wall distance, modified Schober’s test and lumbar lateral flexion) and one hip mobility measurement 
(intermalleolar distance), is commonly used in clinic, and has been demonstrated to be valid and reliable 
(8,9). BASMI is one of the few objective measures of spinal disease progression that does not involve 
imaging.  Since its introduction in 1994 (10), BASMI has been widely used in the research community, 
being cited in over a thousand scientific papers, especially related to clinical interventions and monitoring 
disease progression in clinical trials (9). Although the measurements of BASMI are relatively easy to 
perform (9), they are time consuming and should be conducted in-person by trained health care 
providers. This is particularly relevant in the current context of a pandemic where there is limited 
opportunity for face to face consultation and indeed even afterwards it is likely that remote consultations 
will become more common. 
A meta-analysis published in 2016 emphasised that “spinal mobility indices and original Schober test have 
construct validity for structural damage but do not assess true spinal mobility, nor do they reflect levels of 
inflammation at either the sacroiliac joints and/or the spine.” (9). BASMI score can vary significantly 
within patients, even within the same day (11,12), hence, the relevance of the BASMI score in the daily 
clinical practice has been questioned. A web-based survey of patients and rheumatologists in 2018 
showed that only 65% of rheumatology services in the UK performed BASMI routinely (13). Based on this 
body of evidence there is a question as to whether the BASMI should remain part of the standard 
measures used to evaluate patients.
The aim of this study was to (1) determine the factors associated with decreased spinal mobility (higher 
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Methods
The British Society for Rheumatology Biologic Register for Ankylosing Spondylitis (BSRBR-AS) is a 
prospective UK-wide cohort study of patients who meet ASAS criteria for axSpA (5–7). The study received 
ethical approval from the National Research Ethics Service (NRES) Committee North East – County 
Durham and Tees Valley (REC ref 11/NE/0374).
Patients were recruited in 83 secondary care centres across Great Britain between December 2012 and 
December 2017 and were naïve to biologic therapy on recruitment. Patients meeting the Assessment of 
SpondyloArthritis international Society (ASAS) imaging criteria for axSpA (7) or the modified New York 
(mNY) definition of Ankylosing Spondylitis (AS) were eligible (14). From November 2014 those meeting the 
ASAS clinical criteria were also eligible. Details of the study protocol have previously been published (15). 
There are two participant sub-cohorts: the ‘biologic cohort’, comprising those patients commencing their 
first anti-TNFα therapy (i.e. adalimumab, etanercept, certolizumab pegol) at the time of recruitment and 
the ‘non-biologic cohort’, who were continuing on therapies other than biologics. The follow-up of 
biologic patients included planned assessments at 3, 6 and 12 months.
Data collected at recruitment and follow-up
Clinical data included the BASMI (scored 0 – 10 (least to most severe)) (8,10), body mass index (BMI), 
inflammatory markers (C-Reactive Protein (CRP)), the presence of extra-spinal manifestations (uveitis, 
psoriasis, inflammatory bowel disease (IBD), enthesitis, dactylitis), a count of comorbidities (myocardial 
infarct, angina, heart failure, stroke, hypertension, diabetes, asthma, bronchitis, peptic ulcer, liver and 
renal disease, tuberculosis, demyelination disorders and cancer). We recorded, at the time of recruitment 
only, whether participants met x-ray criteria (signs of bilateral sacroiliitis (at least grade 2) or unilateral (at 
least grade 3)) or MRI criteria (signs of active inflammation suggestive of sacroiliitis). Patient-completed 
questionnaires were used to record demographic and lifestyle factors (tobacco smoking and alcohol 
intake) as well as Bath Ankylosing Spondylitis indices for disease activity (BASDAI) (16), function (BASFI) 
(17) and global assessment (BASG) (18), which were scored in the same way as BASMI. Deprivation 
quintiles, with reference to either the population of Scotland (19), England (20), or Wales (21), were 
determined by participants’ post-codes. Disease specific and general quality of life (QoL) was measured by 
ASQoL (scored 0 (best) - 18 (worst)) (22), whilst general health was measured by Short Form 12 (SF-12) 
(scored 0 (worst) - 100 (best)) (23).
Mental health was assessed by the Hospital Anxiety and Depression Scale (HADS) (0 (best) - 21 (worst)) 
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symptom severity scale (SSS: 0-12) of the 2011 “research criteria” for fibromyalgia (25), fatigue with the 
Chalder Fatigue Scale (CFS, 0-33) (26) and sleep disturbance by the Jenkins Sleep Evaluation Questionnaire 
(0 – 20) (27), with higher scores on each indicating a worse state. Where required, permissions were 
obtained for use of patient-reported measures. 
Outcomes (in the biologics sub-cohort) were measured at the first contact with the study between 10 
weeks and 9 months after commencement of anti-TNF therapy (28). The following response outcomes 
were considered: ASAS20 and ASAS40 (29,30); a clinically important improvement in the Ankylosing 
Spondylitis Disease Activity Score (ASDAS) (a decrease of at least 1.1); moving from a (very)/high to 
moderate or inactive ASDAS disease activity state (score <2.1) (31,32); ASQoL (22). 
Statistical Analysis
For assessing the ability of patient-reported and other clinical factors to estimate BASMI, data used were 
from the time of recruitment. Univariable regression analysis was used to investigate the association 
between BASMI and other variables of interest, with results given as β coefficients (with 95% confidence 
intervals (CI)). These are interpreted as the change in BASMI per one-unit change in each variable 
examined. In order to identify a group of factors independently associated with BASMI, forward stepwise 
regression was used. Factors associated with BASMI at p ≤ 0.2 during univariable analysis were offered as 
candidate variables. Factors entered the model at p ≤ 0.1 and were removed at p > 0.15. Variables for 
which the number of participants was small (n < 750: Polysymptomatic Distress Scale, Somatic Symptoms 
Scale, Generalised Pain, Fibromyalgia and ESR) were excluded. The performance of the model was 
assessed by testing whether the estimated BASMI values were within ± 1 of the measured BASMI values. 
This ± 1 threshold was chosen from a previous study which indicated that a 1-point change in BASMI was 
considered clinically significant (33).
For assessing factors associated with response to therapy, only patients in the biologic sub-cohort were 
eligible. BASMI measured at the time of recruitment (prior to therapy commencement), as well as other 
clinical and patient-reported factors, were assessed in terms of their relationship with outcome. Separate 
models were run for each outcome considered. Univariable regression analysis used logistic regression, 
except for ASQoL where linear regression was used. Factors associated at a significance threshold of p ≤ 
0.2 (including BASMI) were offered to backward stepwise regression models to determine a parsimonious 
group of factors that best predict response. Variables were excluded at p ≥ 0.15 and re-entered at p ≤ 0.1. 
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the increase in odds of the outcome per one unit increase in the predictor variable) and for those with 
linear outcomes, β coefficients are presented (interpreted as the increase in the outcome variable 
(ASQoL) per unit increase in the predictor variable).
All statistical analysis was undertaken using STATA (StataCorp LP version 15) and the final BSRBR:AS study 
download (December 2018) was used.
Results
A total of 1960 participants were eligible for the analysis examining the estimation of BASMI. 
Approximately two-thirds were male (70%), their median age was 48 years (Interquartile range (IQR) 37, 
59) and the median symptom duration 16 years (IQR 7, 30) (Table 1). Of those who had been tested, 80% 
were HLA-B27 positive. Most participants (68%) met the mNY criteria for AS, an additional 29% ASAS non-
radiographic imaging criteria for axSpA, while 3% fulfilled only ASAS clinical criteria for axSpA. The median 
BASMI score was 3.6 (IQR 2.2, 5.3). For BASDAI, BASFI and BASG the median scores were 4.9 (IQR 2.6, 6.8), 
4.5 (IQR 2.0, 7.0) and 5.5 (IQR 2.5, 7.5), respectively.
In the univariable analysis all factors assessed, apart from dactylitis, enthesitis and uveitis, were 
significantly associated with BASMI (Table 2). BASMI score was positively related to all other Bath Indices 
(BASFI β = 0.39 (0.35, 0.42), BASDAI β= 0.24 (0.20, 0.28), and BASG β=0.23 (0.20, 0.26)). Participants who 
were currently employed had a significantly lower BASMI (i.e. better spinal mobility) (β = -1.71 (-1.90, -
1.53)), than those not employed. MRI criteria (signs of active inflammation suggestive of sacroiliitis) was 
associated with a lower BASMI score compared with x-ray evidence of sacroiliitis (bilateral grade 2 or 
unilateral grade 3) (β = -1.62 (-1.88, -1.36)) as was clinical compared with x-ray criteria (β = -1.71 (-2.49, -
0.93)). Higher BASMI scores were observed for participants with comorbidities (per additional 
comorbidity: β = 0.68 (0.57, 0.78)). 
Before undertaking the multivariable model, an assessment for collinearity was conducted and revealed a 
high linear correlation (r > 0.7) between BASFI and five other variables: BASDAI, BASG, ASQoL and SF12-
PCS. As BASFI showed the strongest association with BASMI during univariable regression analysis (β = 
0.39), and is a key target of axSpA management, it was included as a candidate variable for the 
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The final multivariable model (n=1035) included four clinical and four demographic/socio-economic 
factors as independent estimators of BASMI (Table 3). The clinical factors were: BASFI, β = 0.33 (0.30, 
0.36); criteria (MRI (v. x-ray as reference), β = -0.78 (-1.05, -0.52); clinical, β = -0.94 (-1.64, -0.24)); 
symptom duration (years), β = 0.01 (0.002, 0.02)) and CRP, β = 0.01 (-0.002, 0.02)). The 
demographic/socio-economic factors were: age (years), β = 0.03 (0.02, 0.04); gender (female); β = -0.25 (-
0.45, -0.05); current employment, β = -0.23 (-0.45, -0.004); as well as education. The R2 for the fit of the 
model was 0.48 and 51% of the estimated BASMI values were within ± 1 of the measured BASMI values 
(Figure 1). Estimation was better for patients with BASMI in the mid-range with the model 
underestimating all people with measured BASMI above 7.
A total of 204 participants were eligible for the analysis examining predictors of response to biologic 
therapy. Their median age was 48 years (IQR 38, 56), 73% were male and the median follow-up duration 
was 13.9 weeks (IQR 12.6, 16.4). Of those who had been tested, 79% were HLA-B27 positive. Most 
participants (81%) met the mNY criteria for AS, an additional 17% ASAS imaging criteria, while 2% fulfilled 
only ASAS clinical criteria for axSpA. At baseline the median BASMI was 4.6 (IQR 3.0, 5.8) and median 
ASDAS 3.7 (IQR 3.2, 4.5). At follow-up, 51% and 30% of participants met ASAS20 and ASAS40 response 
criteria respectively. BASMI measured at recruitment was an independent predictor of both ASAS20 and 
ASAS40 response with effect measures of response per unit increase, of OR 0.80, 95% CI (0.66, 0.98) and 
OR 0.69, 95% CI (0.50, 0.95) for ASAS20 and ASAS40 respectively (Table 4). Other significant factors 
included in the models predicting non-response were higher BMI (both models) and smoking, absence of 
enthesitis and higher levels of anxiety (ASAS40 only). BASMI was also an important predictor of poor QoL 
(β 0.64 95% CI (0.26, 1.02)) and other predictors were poorer QoL at recruitment, higher levels of 
deprivation, a higher BMI and tender joint count, as well as higher levels of anxiety. In contrast, BASMI 
was not retained in the models based on either the change in, or final level of, ASDAS (Table 4). The 
outcome of clinically important change in ASDAS was dominated by the initial level of ASDAS while 
prediction of a final low level of ASDAS only had a single significant predictor – low levels of anxiety.
Discussion
Decreased spinal mobility in patients with axSpA is associated with decreased physical function, being 
older, male gender, longer symptom duration, not in current employment, lower level of education, 
meeting X-ray criteria for AS, and having a higher CRP. However, the ability to estimate BASMI based on 
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BASMI is an independent predictor of treatment response when response is defined in terms of 
ASAS20/40 or quality of life, but not ASDAS.
The BSRBR-AS registry comprises a relatively large cohort of participants compared to other studies 
assessing BASMI in the scientific literature (34–39). Most patients seen in rheumatology clinics would 
have been eligible and recruiting centres included teaching and district general hospitals covering wide 
geographic areas. The presented analysis has certain limitations. The patient reported data and the 
measurement of BASMI was not at the same time. BASMI was collected during the routine clinical visit 
while the patient-reported information was provided when completing the postal-delivered questionnaire 
which would be received around the time of the first expected routine visit after starting anti-TNF 
therapy. The measurements of BASMI were at a single point of time and will be subject both to short-
term variation which occurs in individuals and measurement error. However, these issues would make it 
more difficult to estimate BASMI and the data would underestimate the performance of a model so to do. 
Participants in the dataset predominantly fulfilled the mNY criteria with established x-ray changes (68%), 
thus, the presented model might be different in a cohort with more non-radiographic axSpA participants, 
as BASMI scores appear to be lower in this population (34). Whenever there is missing data, there is the 
possibility of selection bias. This is a particular issue when measuring the prevalence of a disease, 
symptom or other disease attribute. It is less of a concern when we are measuring the relationship 
between variables; this should still be unbiased unless there is a different relationship between BASMI 
and other characteristics in people who had BASMI measured compared to those who did not.
The associations identified here account for around 50% of the variance in BASMI (although as noted 
above that for methodological reasons this is likely to be an underestimate). This could be due to several 
reasons; the BASMI may capture something that other measurements do not or there might be other 
measurements which could estimate BASMI better, but the BSRBR-AS did not collect them (such as more 
detailed information on imaging). Other than having more detailed information available from imaging 
(rather than just which criteria are met), it is difficult to identify what these missing factors might be, as 
the data collected within the BSRBR-AS is based on consensus meetings with consultant rheumatologists 
to reflect routine clinical practice in the UK and was supervised by an international steering committee. 
While we show a relationship (on univariable analysis) between mental health measures and BASMI, the 
data presented here do not allow us to draw conclusions on the temporal nature of this relationship. It 
could be that mental health directly influences BASMI, but more likely that persons with severe disease 
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The model estimating BASMI did not perform well for persons with high measured BASMI. The estimated 
score for all persons with a BASMI over 7 was an underestimate, sometimes by a considerable amount. In 
a supplementary (unplanned) logistic regression we looked at what factors were associated with having a 
BASMI >7. Longer disease duration, male gender, meeting X-ray criteria, not currently working and higher 
levels of anxiety were all significantly related but the fit of the model was poor (R2=0.16) (data not 
shown). The first three factors directly contribute to disease progression and hence poor mobility, while 
the remaining two factors are likely (at least in part) a consequence of poor mobility.  It would be 
important to understand better what factors result in persons having very poor spinal mobility.  
Several studies have attempted to identify factors associated with the spinal mobility of axSpA patients. 
Calvo-Gutierrez, et al. (2015) (37) in a study of 50 patients found that the UCOASMI (University of 
Cordoba Ankylosing Spondylitis Metrological Index) was independently predicted by structural damage, 
higher disease activity, older age and longer symptom duration. This is similar to the findings from the 
current study. Another small study (n=81) based on data collected prospectively in Turkey, also found an 
independent association between BASMI and older age (years) (β = 0.4), male gender (β = 0.2), HLA-B27 
positivity (β = - 0.2) and longer disease duration (years) (β = 0.3) (38). A longitudinal mixed model (39), 
based on the German Spondyloarthritis Inception Cohort data (n = 210), found an independent 
association between BASMI and the sacroiliitis sum score (β= 0.12 (95%CI 0.03, 0.21), which is in line with 
our finding that X-ray evidence of sacroiliitis is associated with poorer spinal mobility. 
There are only a few studies examining whether BASMI is a predictor of treatment response; in a study of 
624 participants with axial SpA in Switzerland who were starting TNFi therapy, high BASMI was a 
significant predictor of a not satisfying ASAS40 response criteria at one year follow-up (OR 0.76 per unit 
increase, 95% CI 0.63, 0.90) (40). BASMI score on commencing TNFi therapy was a predictor of better 
physical function and spinal mobility at three-year follow-up in a study of 257 AS patients from The 
Netherlands (41), however BASMI was not an independent predictor of inactive disease (defined by 
ASDAS<1.3) in a study of 117 AS patients treated with TNFi in Brazil (42). All these results are in 
agreement with those from the current study. Other prospective studies of treatment response have not 
considered or included BASMI as a potential predictor (43). 
In a five-year prospective study of 166 axSpA patients in Sweden, high BASMI predicted radiographic 
progression, although only in women (44). In a recent meta-analysis examining factors associated with 
high IL-23 levels in axSpA patients, including 10 studies with 1724 patients, BASMI was one of two factors 
along with inflammatory markers (ESR and CRP) to be positively associated (correlation co-efficient 0.46, 
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correlation with IL-6 (46). Mewes et al (2019) in a small study of 55 patients with axSpA showed a strong 
association between a high BASMI score and poor balance, which in turn was linked to a higher risk of falls 
(47). 
The current study identified that BASMI was reasonably well estimated by other patient-reported and 
routinely available clinical data. However high measured BASMI scores in particular were not well 
estimated. Clinical assessments are time consuming and need trained staff (9), although the results from 
this study show that amongst persons commencing biologic therapy, BASMI was an independent 
predictor of response for some but not all recognised response criteria. BASMI does not routinely feature 
in evidence-based guidelines for management of axSpA. For example, the NICE treatment 
recommendation (48) makes no mention of BASMI or spinal mobility while the ASAS-EULAR 
recommendations mentions “spinal mobility” as one aspect of the disease for monitoring (49). However, 
ASAS positively recommends a set of measurements which overlap with but are not identical to the 
BASMI (50). We also noted in our current study that some centres (27%) did not routinely measure 
BASMI. This suggests, while the measurement of spinal mobility provides additional information on 
disease status and for some measures of treatment response, it remains to be determined how this 
should be incorporated into disease monitoring and clinical decision making, particularly in circumstances 
where face to face consultations are likely to become less frequent. 
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Table 1. Characteristics of the BSRBR-AS patients with measured BASMI
Variable N % or Median (IQR)*
Spinal Mobility BASMI: 0 (best) – 10 (worst) 1960 3.6 (2.2, 5.3)
Demographic factors
Age Years 1960 47.8 (36.6, 59.0)
Gender Male 1375 70.2
Female 585 29.8
Education Secondary school 520 33.1
Apprenticeship 154 9.8
Further education college 487 31.0
University degree 302 19.2
Further degree 109 6.9
Currently employed No 586 37.0
Yes 988 63.0





quintiles of general population 
5. least deprived 340 17.4
Smoking status Never 670 43.0
Ex 571 36.7
Current 316 20.3








Disease Activity BASDAI: 0 (best) – 10 (worst) 1560 4.9 (2.6, 6.8)
Physical Function BASFI: 0 (best) – 10 (worst) 1574 4.5 (2.0, 7.0)
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Quality of Life ASQoL: 0 (best) – 18 (worst) 1561 9 (3, 14)
SF-12 – MCS 0 (worst) – 100 (best) 1536 47.1 (37.5, 55.3)
SF-12 – PCS 0 (worst) – 100 (best) 1536 39.2 (29.8, 48.5)
Chalder Fatigue 0 (best) – 33 (worst) 1579 14 (11, 19)
Jenkins Sleep Evaluation 0 (best) – 20 (worst) 1571 10 (5, 15)
Widespread Pain Index 0 (best) – 19 (worst) 751 4 (2, 7)
Somatic Symptoms Scale 0 (best) – 32 (worst) 582 5 (3, 8)
Polysymptomatic Distress 
Scale 
0 (best) – 31 (worst) 582 10 (7, 14)
Generalised Pain No 453 68.9
Yes 204 31.1
Fibromyalgia No 477 73.0
Yes 176 27.0
Depression HADS:  0 (best) – 21 (worst) 1561 5 (2, 9)
Anxiety HADS:  0 (best) – 21 (worst) 1561 7 (4, 11)
Clinical factors
Symptom duration Years 1960 16.0 (7.0, 29.5)
axSpA classification Modified New York 1337 68.2
ASAS imaging (not mNY) 558 28.5
ASAS clinical 65 3.3
HLA-B27 Positive 999 51.0
Negative 252 12.9
Unknown 709 36.2
Criteria X-Ray 1382 83.4
MRI 251 15.1
Clinical 24 1.5
Comorbidity Count Range: 0 - 5 1950 0 (0, 1)
Uveitis No 1461 74.9
Yes 489 25.1
No 1755 90.0Inflammatory Bowel Disease 
Yes 195 10.0
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Yes 212 10.9
Dactylitis No 1858 95.3
Yes 92 4.7
Enthesitis No 1740 89.2
Yes 210 10.8
Body Mass Index kg/m2 1716 27.1 (24.1, 30.8)
C-reactive Protein mg/dL 1544 0.6 (0.2, 2.0)
ESR mm 745 11 (5, 23)
*% given for discrete variables, median (IQR) for continuous variables.
BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; BASFI, Bath Ankylosing Spondylitis 
Functional Index; BASMI, Bath Ankylosing Spondylitis Metrology Index; BASG, Bath Ankylosing 
Spondylitis Global score; SF-12 – MCS, Mental Component of the Short-Form 12 Health Survey; SF-
12 – PCS, Physical Component of the Short-Form 12 Health Survey; CRP, C – reactive protein; 
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Age* 1960 Per year 0.06 (0.05, 0.07)
Gender* 1960 Female vs male -0.58 (-0.78, -0.39)
Education* Secondary school Ref.1572




University degree -1.32 (-1.59, -1.05)
Further degree -1.27 (-1.66, -0.87)
Currently employed* 1574 Yes vs no -1.71 (-1.90, -1.53)
Deprivation* 1957 Per increasing category 0.09 (0.02, 0.16)
Smoking status* 1557 Ex vs never 0.61 (0.39, 0.83)
Current vs never 0.75 (0.47, 1.00)
1559 Ex vs never -0.01 (-0.44, 0.42)Alcohol consumption* 
Current vs never -0.84 (-1.21, -0.46)
Patient reported factors
Disease Activity (BASDAI)* 1560 Per unit increase 0.24 (0.20, 0.28)
Physical Function
(BASFI) *




1563 Per unit increase
0.23 (0.20, 0.26)
Quality of Life (ASQoL)* 1561 Per unit increase 0.12 (0.09, 0.13)
SF-12 – MCS* 1536 Per unit increase -0.01 (-0.02, -0.01)
SF-12 – PCS* 1536 Per unit increase -0.07 (-0.08, -0.06)
Chalder Fatigue* 1579 Per unit increase 0.04 (0.02, 0.06)
Jenkins Sleep Evaluation* 1571 Per unit increase 0.05 (0.03, 0.06)
Widespread Pain Index* 751 Per unit increase 0.10 (0.06, 0.14)
Somatic Symptoms Scale* 582 Per unit increase 0.08 (0.02, 0.13)
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Generalised Pain* 747 Yes vs no 0.89 (0.57, 1.21)
Fibromyalgia* 653 Yes vs no 0.64 (0.30, 0.98)
Depression* 1561 Per unit increase 0.11 (0.09, 0.13)
Anxiety* 1561 Per unit increase 0.04 (0.02, 0.06)
Clinical factors
Symptom duration* 1960 Per year 0.05 (0.04, 0.05)
HLA-B27* 1251 Negative vs positive 0.31 (0.04, 0.59)
Criteria* 1657 X-Ray Ref.
MRI -1.62 (-1.88, -1.36)
Clinical -1.71 (-2.49, -0.93)
Comorbidity Count* 1950 Per unit increase 0.68 (0.57, 0.78)
Uveitis 1950 Yes vs no 0.06 (-0.14, 0.27)
Inflammatory Bowel Disease* 1950 Yes vs no 0.53 (0.23, 0.83)
Psoriasis* 1950 Yes vs no 0.40 (0.11, 0.64)
Dactylitis 1950 Yes vs no -0.03 (-0.45, 0.38)
Enthesitis 1950 Yes vs no 0.22 (-0.06, 0.50)
Body Mass Index* 1716 Per unit increase 0.06 (0.03,0.08)
CRP* 1544 Per unit increase 0.01 (0.00, 0.02)
ESR* 745 Per unit increase 0.02 (0.01, 0.03)
* eligible for stepwise model (p<0.2)
ASQoL, Ankylosing Spondylitis Quality of Life Questionnaire; BASDAI, Bath Ankylosing Spondylitis 
Disease Activity Index; BASFI, Bath Ankylosing Spondylitis Functional Index; BASMI, Bath Ankylosing 
Spondylitis Metrology Index; BASG, Bath Ankylosing Spondylitis Global score; SF-12 – MCS, Mental 
Component of the Short-Form 12 Health Survey; SF-12 – PCS, Physical Component of the Short-Form 
12 Health Survey; CRP, C – reactive protein; HADS, Hospital Anxiety and Depression Scale; Jenkins, 
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Table 3. Results of the stepwise forward model to estimate BASMI
Variables Regression coefficient β (95% CI)
Physical Function (BASFI) Per unit increase 0.33 (0.30, 0.36)
Age Per year 0.03 (0.02, 0.04)
Criteria X-Ray Ref.
MRI -0.78 (-1.05, -0.52)
Clinical -0.94 (-1.64, -0.24)
Symptom duration Per year 0.01 (0.002, 0.02)
Current employment Yes vs. no -0.23 (-0.45, -0.004)
CRP Per unit increase 0.01 (-0.002, 0.02)
Gender Male Ref.
Female -0.25 (-0.45, -0.05)
Education Secondary school Ref.
Apprenticeship -0.13 (-0.45, 0.19)
Further education college -0.18 (-0.41, 0.04)
University degree -0.33 (-0.59, -0.07)
Further degree -0.40 (-0.79, -0.02)
Number of obs. R-square Adj. R-square
1,035 0.4824 0.4764
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Figure 1. Predictive performance of the final multivariable linear regression model. A hypothetical perfect 
model would align all points on the 45o continuous red line. The points within the 45o red dotted lines 
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Table 4. Factors at recruitment associated with response to biologic therapy
Response criteria ASAS20 ASAS40 Δ ASDAS ≥ 1.1 ASDAS < 2.1 ASQoL*
N participants in model N=157 N=144 N=151 N=149 N=157
% meeting criteria 51% 30% 47% 31% Not applicable
Variables at 
recruitment
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)  (95% CI)
BASMI Per unit increase 0.80 (0.66, 0.98) 0.69 (0.50, 0.95) 0.64 (0.26, 1.02)
Age Per unit increase 0.96 (0.93, 1.003) 0.97 (0.93, 1.004)
Education Secondary school Ref.      
Apprenticeship 2.72 (0.72, 10.2)
College 0.77 (0.25, 2.44)
University degree 2.29 (0.81, 6.50)
Further degree 3.74 (0.69, 20.6)
Deprivation per increasing category 0.77 (0.56, 1.06) 0.60 (0.12, 1.07)
Smoking status Never    Ref.     
Ex 0.47 (0.17, 1.29)
Current 0.22 (0.06, 0.79)










This article is protected by copyright. All rights reserved
Ex 1.25 (0.27, 5.75)
Current   3.02 (0.86, 10.64)
Body Mass Index Per unit increase 0.93 (0.87, 0.99) 0.89 (0.81, 0.97) 0.14 (0.02, 0.26)
BASFI Per unit increase 1.47 (0.99, 2.20)
Enthesitis Yes vs no 3.72 (1.03, 13.4) 5.87 (1.28, 26.97)
SF-12 – MCS Per unit increase 1.06 (1.01, 1.10)
SF-12 – PCS Per unit increase 1.06 (0.99, 1.12)
ASDAS Per unit increase 1.28 (0.90, 1.81) 1.90 (0.99, 3.64) 5.25 (2.90, 9.50) 0.77 (0.50, 1.17)
ASQoL 0.51 (0.33, 0.68)
Comorbidity count Per unit increase 0.42 (0.24, 0.71) 0.54 (0.29, 1.02)
Tender joints count 0.83 (0.67, 1.02) 0.19 (0.05, 0.33)
HADS anxiety 0.87 (0.78, 0.97) 0.84 (0.76, 0.94) 0.24 (0.07, 0.41)
CRP 0.94 (0.88, 1.01)
*ASQoL measured at follow-up
OR, odds ratio; , linear regression coefficient; Ref, reference category; ASAS, Assessment in Ankylosing Spondylitis; ASQoL, Ankylosing Spondylitis Quality of Life 
Questionnaire;  BASMI, Bath Ankylosing Spondylitis Metrology Index; ASDAS, Ankylosing Spondylitis Disease Activity Score; BASFI, Bath Ankylosing Spondylitis 
Functional Index; SF-12 – MCS, Short Form 12 Mental Component Score; SF-12 – PCS, Short Form 12 Physical Component Score; HADS, Hospital Anxiety and 
Depression Scale; CRP, C – reactive protein. 
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